Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Northwest Biotherapeutics, Inc." (NWBO) Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Northwest Biotherapeutics, Inc." (NWBO)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: SVA, EXEL, ENZY, SPHS

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Northwest Biotherapeutics, Inc."© quotemedia

Company Profile

Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancers in the United States. Its DCVax uses activated dendritic cells to mobilize a patientís own immune system to attack their cancer. The company develops DCVax-L, which is under Phase III clinical trials for glioblastoma multiforme brain cancer and ovarian cancer, and for other cancers in situations, which the patient has their tumor surgically removed as part of standard of care; DCVax-Direct for patients with various metastases or have cancers that are relatively accessible for injections, such as head, neck, liver, and pancreatic cancers; and DCVax-Prostate that is under Phase III clinical trial for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Recent News: "Northwest Biotherapeutics, Inc."